## THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Donald L. Durden

Serial No. : 10/712,850

Filing Date : November 13, 2003

Examiner : Yu, Misook

Group Art Unit : 1642

Entitled : "Compositions and Methods for

Identifying Agents Which Modulate PTEN Function and PI-3

Kinase Pathways"

Suite 2400 1601 Market Street Philadelphia, PA 19103 (215) 563-4100 (telephone) (215) 563-4044 (facsimile) Our File No. 1857-IURTC.0024US-CON

## UNDER 37 C.F.R. §1.97

Dear Sir:

In compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, Applicant is submitting herewith 1 sheet of Form PTO/SB/08b and a copy of the non patent reference listed thereon. This Information Disclosure Statement is being filed more than three months after the filing date, but before receipt of the first Official Action on the merits. Thus, it is believed by the undersigned that no fee is required under 37 C.F.R. §1.97(b).

This submission is not an admission that the reference listed on the attached Form PTO/SB/08b constitutes prior art against the claims of this application.

The Examiner is respectfully requested to confirm receipt and consideration of the cited reference by initialing and

U.S. Patent Application No. 10/712,850

returning a copy of the attached Form PTO/SB/08b in accordance with MPEP §609.

In the event that a fee is required in connection with this submission and not enclosed, the Commissioner is authorized to charge Deposit Account No. 04-1406 of the undersigned attorneys.

Early and favorable consideration of this application is respectfully requested.

Agent for Applicants

Respectfully submitted, DANN, DORFMAN, HERRELL AND SKILLMAN A Professional Corporation

Robert C. Netter, Jr., Ph.D.

Robert C. Netter, Jr., Ph.D. Registration No. 56,422

RCN:LCF
Attachments- Form PTO/SB/08b
- Copy of non patent reference

PTO/SB/08B (04-07)

Approved for use through 09/30/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	re required to respond to a collection of information unless it contains a valid OMB control number.  Complete if Known			
Substitute for form 1449/PTO	Application Number	10/712,850		
INFORMATION DISCLOSURE	Filing Date	November 13, 2003		
STATEMENT BY APPLICANT	First Named Inventor	Donald L. Durden		
	Art Unit	1642		
(Use as many sheets as necessary)	Examiner Name	Yu, Misook		
Sheet 1 of 1	Attorney Docket Number	1857-IURTC.0024-US-CON		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	C1	ZHONG, H., et al., "Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol", Cancer Res. 60:1541-1545 (March 15, 2000)		

Examiner		Date	
Signature		Considered	
*EXAMINER: In	nitial if reference considered, whether or not citation is in conformance with MPEP 60	<ol><li>Draw line through c</li></ol>	itation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicants in unique clatation designation number (optically 2 Applicants in the place) a check mark here if English language Transistion is statished.

This collection of information is required by 37 CFR 1.98. This information is required to the propose of the propose o Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.